Mechanical thrombectomy for mild stroke with anterior circulation large vessel occlusion: a multicenter cohort study

Gaopan Zhang, N. Zhang, Jingfan Li, Siyu Zhang, Ming Li, Xiongfei ZhaoFrontiers in Neurology 2025 · DOI

TL;DR

For patients with "mild" strokes (NIHSS < 6) caused by a large vessel occlusion (mELVO), this multicenter study found no statistically significant difference in 90-day recovery or safety between invasive mechanical thrombectomy (MT) and standard medical management (MM). While MT showed a numerical trend toward better functional independence, the added risk of procedural complications suggests that conservative medical treatment remains a viable—and perhaps safer—first-line approach until randomized trials prove otherwise.

What Problem Does This Paper Address?

In the world of stroke neurology, "Large Vessel Occlusion" (LVO) is usually a red alert. It means a major artery in the brain is blocked, typically requiring Mechanical Thrombectomy (MT)—a surgical procedure to physically pull the clot out. Current guidelines strongly recommend MT for patients with a National Institutes of Health Stroke Scale (NIHSS) score of 6 or higher.

However, there is a clinical "gray zone": patients with an LVO who present with very mild symptoms (NIHSS < 6). These patients are often excluded from major clinical trials. Doctors face a dilemma: do you perform an invasive surgery with risks of hemorrhage to clear a major blockage, or do you stick to medical management (like blood thinners) because the patient currently looks "fine"? This study investigates whether the aggressive surgical approach actually leads to better long-term outcomes for these "mild" cases.

Methods

The researchers conducted a multicenter retrospective cohort study across three stroke centers in China, analyzing 140 patients treated between March 2020 and June 2024.

To compare the two treatment groups fairly, they used Inverse Probability of Treatment Weighting (IPTW). This statistical technique helps balance baseline differences (like age, stroke severity, and the specific site of the blockage) between the MT group (48 patients) and the MM group (92 patients), effectively mimicking the balance of a randomized controlled trial in a retrospective dataset.

The primary endpoint was an "excellent outcome" at 90 days, defined as a modified Rankin Scale (mRS) score of 0–1 (no significant disability).

Datasets

The study utilized a specific patient cohort rather than a public dataset:

  • Source: Three stroke centers in China (Xianyang and Yulin).
  • Population: 140 individuals with mELVO (NIHSS < 6, anterior circulation occlusion).
  • Timeframe: March 2020 to June 2024.

Key Insights and Ideas

  • The "Stable" Paradox: Patients with mild symptoms and a major blockage are often stable because of "collateral circulation"—secondary blood vessels that bypass the clog. The study suggests that for these patients, the brain might be compensating well enough that the risks of surgery (like symptomatic intracranial hemorrhage) outweigh the benefits of immediate recanalization.
  • Numerical vs. Statistical Significance: Interestingly, the MT group had a higher raw percentage of functional independence (85.4% vs 71.7% for MM). However, when adjusted for baseline risks and sample size, this difference was not statistically significant.
  • Occlusion Site Bias: Patients selected for MT were significantly more likely to have an Internal Carotid Artery (ICA) occlusion (50% vs 19.6% in the medical group). This suggests surgeons are more likely to intervene when the "top" of the arterial tree is blocked, even if symptoms are mild.

Key Results

  • Excellent Outcomes (mRS 0-1): No significant difference. The adjusted Odds Ratio (aOR) was 0.93 (95% CI, 0.41–2.11).
  • Functional Independence (mRS 0-2): While the MT group looked better on paper (aOR 2.14), the confidence interval (0.77–5.91) crossed 1.0, meaning the result wasn't statistically robust.
  • Safety Endpoints:
    • sICH (Hemorrhage): Numerically higher in the MT group (8.3% vs 5.4%), but not statistically significant (aOR 1.63).
  • Mortality: Very low in both groups (2.1% for MT vs 3.3% for MM).
  • Time Window: Stratifying patients by "early" (≤6h) vs "late" (6-24h) arrival did not change the results; MM remained comparable to MT in both windows.

Limitations and Future Work

The authors acknowledge several key limitations:

  1. Sample Size: With only 140 patients, the study may be underpowered to detect smaller, potentially meaningful benefits of MT.
  2. Retrospective Design: Despite using IPTW, there is always a risk of "selection bias"—doctors might have chosen MT for patients they perceived as having a higher risk of deteriorating.
  3. Collateral Data: The study lacked detailed imaging of collateral blood flow, which is a major predictor of whether a "mild" stroke will stay mild or get worse.
  4. Future Direction: The authors conclude that while MT isn't currently superior to medical management for mild strokes, large-scale Randomized Controlled Trials (RCTs) are necessary to definitively settle the debate.

Summary updated

Abstract

Among patients with mELVO, MT was not associated with significantly different outcomes compared to MM. Further investigation through randomized controlled trials is warranted.
BibTeX
@inproceedings{zhang2025mechanical,
  author = {Gaopan Zhang and N. Zhang and Jingfan Li and Siyu Zhang and Ming Li and Xiongfei Zhao},
  title = {{Mechanical thrombectomy for mild stroke with anterior circulation large vessel occlusion: a multicenter cohort study}},
  booktitle = {Frontiers in Neurology},
  year = {2025},
  doi = {10.3389/fneur.2025.1668704},
}
Figure